business
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
Key takeaways
- The fund acquired 354,575 shares, with an estimated transaction value of $4.19 million based on the average closing price for the period.
- This was a new position for the fund, representing 4.05% of reported U.S. equity holdings as of March 31, 2026
- NASDAQ: PRAX: $27.35 million (19.8% of AUM)
Cory Renauer, The Motley Fool Sat, May 16, 2026 at 10:01 PM GMT+7 4 min read ERAS PRAX TERN WHWK TNGX What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca (NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4.19 million based on the average closing price for the period. The quarter-end value of the stake rose to $5.74 million, a change reflecting both the share addition and price fluctuations during the quarter.
This was a new position for the fund, representing 4.05% of reported U.S. equity holdings as of March 31, 2026
NASDAQ: PRAX: $27.35 million (19.8% of AUM)
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop